

Epidemiology of *Acinetobacter baumannii* Isolates in an Intensive Care Unit in Kazakhstan

Nelya Bissenova, Aigerim Yergaliyeva

National Scientific Medical Research Center, Laboratory of Microbiology, Astana, Kazakhstan

ABSTRACT

Objective: Objectives: *Acinetobacter baumannii* is an important pathogen of infections in many hospitals, especially in intensive care unit patients, conditioned difficulty to control spread and treatment. The objective of the present study is to report the prevalence and antibiotic resistance rates of *A. baumannii* strains in ICU patients during a five-year period in a tertiary care hospital in Kazakhstan.

Methods: Consecutive, non – duplicate isolates of *A. baumannii* were collected and processed during the course of routine diagnostic work up from adult patients hospitalized in ICU. Identification of isolates and antibiotic susceptibility testing were performed by Vitek 2 automated system.

Results: In total 325 *A. baumannii* strains were evaluated. The most frequent of strains were from tracheostomy tubes (67 isolates, 22.1%), followed by tracheal aspirates (58 isolates, 19.1%) and urinary tract (47, 15.5%). The prevalence of *A. baumannii* strains in ICU was significantly increased from 6.9% in 2011 to 34.1% to 2015 ($p=0.002$). Most of testing isolates were 96.7% and higher resistant to cephalosporins, carbapenems, quinolones. Lower resistance 50% and highest was obtained to aminoglycosides.

Conclusion: we report for the first time in Central Kazakhstan the prevalence and resistance rates of *A. baumannii* in ICU in a single tertiary hospital. The present report is alarming because the increasing resistance can lead to no alternative situation on the choice of drugs for the casual treatment of infections caused by extremely resistant *A. baumannii* strains. *J Microbiol Infect Dis* 2018; 8(3):83-88.

Keywords: *Acinetobacter baumannii*, carbapenems, increasing resistance, intensive care, prevalence

INTRODUCTION

Acinetobacter baumannii is an important pathogen of infections in many hospitals, especially in intensive care unit patients, conditioned difficulty to control spread and treatment.

The incidence of *A. baumannii* infections has continuously increased, due to the increasing proportion of seriously ill patients who require advanced medical support [1-5,10]. *A. baumannii* associated infection in ICU characterized rapidly developing resistance to multiply antimicrobial agents, prolong hospital stay and increasing morbidity and mortality [6-7].

Currently, *A. baumannii* is an important agent of infection in ICU patients for which effective

therapy is limited [8]. Given inappropriate initial antimicrobial therapy of multidrug resistant *A. baumannii* infection is a strong predictor for mortality [9].

Antibiotic resistance of *A. baumannii* strains is considerably different among countries, hospitals and even departments. These differences condition different patterns of antimicrobial usage and different antimicrobial control measures and policies [10].

All these findings support the need of strict adherence to monitoring antibiotic resistance of *A. baumannii* strains in intensive care unit, together with the control measures to prevent the spread of multi-drug resistant strains. The objective of the present study is to report the prevalence and antibiotic resistance rates of *A.*

Correspondence: Dr. Nelya Bissenova, Laboratory of Microbiology of National Scientific Medical Research Center, 42 Abylaikhan Avenue, Astana, Kazakhstan
Email: nelyabis@mail.ru

Received: 26 March 2018 Accepted: 22 July 2018

Copyright © JMID / Journal of Microbiology and Infectious Diseases 2018, All rights reserved

baumannii strains in ICU patients during a five-year period in a tertiary hospital of Kazakhstan.

METHODS

Study design

This prospective study was carried out over a period from January 2011 to December 2015 in the Department of Microbiology, of JSC National Scientific Medical Research Center located in Astana, Kazakhstan.

Data collection

Consecutive, non-duplicate (325) isolates of *A. baumannii* were collected and processed during the course of routine diagnostic work up from adult patients hospitalized in ICU after cardiac surgery (surgery on the heart and major blood vessels). All patients in the ICU were monitored for bacterial infection at body sites for a period of at least one month. Strains were analyzed by infection site and pathogen type.

Respiratory tract specimens included sputum, tracheal aspirate, tracheostomy tube, bronchoalveolar lavage. Urethral tract included urine samples, collected through the urinary catheter. Other types of specimens obtained from the patients were: blood specimens, wound samples and drainage. All specimens were collected at the bed site, transported to the Laboratory of Microbiology and were inoculated on proper culture media within two hours according to the guidelines [11].

Samples cultivation

Clinical specimens were inoculated onto 5% sheep blood agar, Mannitol salt agar, Endo agar, Sabouraud dextrose agar (Himedia, India). Plates were incubated at 37 °C for 18-24 hours.

Identification of isolates

Methods used for confirmation of identification included test of colonial morphology, hemolytic activity on appropriate agar media, Gram stain, rapid tests (coagulase, oxidase, catalase, indole) and use of automated identification system Vitek 2 – Compact (bioMérieux, Marcy l'Etoile, France).

Antibiotic susceptibility testing

Susceptibility tests were performed with broth microdilution method (Vitek 2-Compact,

bioMérieux, Marcy l'Etoile, France) for following antibiotics: meropenem, imipenem, amikacin, gentamicin, tobramycin, ciprofloxacin, levofloxacin and colistin. Colonies from 18-24 hours culture were used to inoculate the microdilution cards. Disk diffusion method was used to netilmicin. The diameter of inhibition zones was measured according to the standards of the EUCAST (version 5.0) and data were reported as susceptible and resistant.

All data were analyzed using Microsoft Access and Excel. Trends over time of antibiotic resistance rates were determined by linear regression with the yearly data. A p value of <0.05 was considered to be statistically significant.

Data were entirely anonymised throughout the entire study and thus ethical approval was not needed.

RESULTS

During the study period from January 2011 to December 2015 of the total cultures processed, the number of pathogenic bacterial isolates was 1515, of them 869 constituted (57.3%) gram negatives, 564 (37.2%) gram positive and 82 (5.4%) fungi. Overall, *A. baumannii* isolated constituted 34.8% of the total gram negative load (303 out of 869). The prevalence of *A. baumannii* strains was 20% of the total isolates.

The maximum number of *A. baumannii* strains were isolated from tracheostomy tube 67 (22.1%), followed by 58 (19.1%) in tracheal aspirate and 47 (15.5%) in urinary tract (Table 1).

During study period from blood specimens were isolated 6.7% (22) strains of *A. baumannii*. The prevalence of *A. baumannii* strains in ICU was significantly increased from 6.9% in 2011 to 34.1% to 2015 ($p=0.002$). The resistance distributions of *A. baumannii* strains and changes in their distributions by year are shown in (Table 2). All strains were resistant to piperazillin-tazobactam. Resistance to ceftazidime, meropenem, imipenem, tobramycin, gentamicin, ciprofloxacin, and norfloxacin gradually and dramatically increased over time. Most of testing isolates were 96.7% and higher resistant to carbapenems and quinolones. Lower resistance 50% and highest was obtained to aminoglycosides.

Table 1. The changes in detection rate of isolates by years (2011-2015) reported from intensive care unit.

Microorganism, (n (%))	2011	2012	2013	2014	2015	Total	p-value ³
Sputum	0	6 (16.7)	8 (22.2)	11 (30.6)	11 (30.6)	36 (11.9)	0.018
Tracheal aspirate	5 (8.6)	4 (6.9)	15 (25.9)	17 (29.3)	17 (29.3)	58 (19.1)	0.040
Tracheostomy tube	1 (1.5)	9 (13.4)	15 (22.4)	13 (19.4)	29 (43.3)	67 (22.1)	0.023
BAL ¹	4 (10.5)	4 (10.5)	8 (21.1)	10 (23.6)	12 (31.6)	38 (12.5)	0.005
Urinary tract	5 (10.6)	6 (12.8)	12 (25.5)	11 (23.4)	13 (27.7)	47 (15.5)	0.031
Wound samples	5 (11.4)	7 (15.9)	10 (22.7)	8 (18.2)	14 (31.8)	44 (14.5)	0.049
Drainage	0	1 (7.7)	2 (15.4)	3 (23.1)	7 (53.8)	13 (4.2)	0.019
BSI ²	3 (13.6)	3 (13.6)	4 (18.1)	5 (22.7)	6 (27.2)	22 (6.7)	0.006
Total	24 (7.3)	41 (12.6)	73 (23.4)	78 (24)	109 (33.5)	325	0.002

Table 2. Antibiotic resistance rates of *A. baumannii* isolated from patients in ICU

Antibiotic (n (%))	2011 n=24	2012 n=41	2013 n=73	2014 n=78	2015 n=109	p-value*
Meropenem	18 (75)	30 (73.1)	60 (80.8)	74 (94.8)	100	0.016
Imipenem	12 (50)	32 (78.0)	67 (91.7)	74 (94.8)	100	0.027
Amikacin	13 (54.1)	21 (51.2)	45 (61.6)	66 (84.6)	88 (80.7)	0.041
Tobramycin	4 (16.6)	8 (19.5)	17 (23.2)	41 (52.5)	80 (73.3)	0.021
Gentamicin	7 (29.1)	26 (63.4)	51 (69.8)	56 (71.7)	91 (83.4)	0.037
Netilmicin	0	0	4 (5.4)	26 (33.3)	55 (50.4)	0.223
Ciprofloxacin	22 (91.6)	39 (95.1)	69 (94.5)	75 (96.1)	100	0.024
Levofloxacin	21 (87.5)	36 (87.8)	69 (94.5)	101 (92.6)	100	0.032

*Linear regression

DISCUSSION

As is known, antibiotic resistance keeps increasing among gram-negative pathogens from ICU patients. Particularly, *A. baumannii* display pun drug and extremely drug resistances that it making therapy selection difficult and impossible. *A. baumannii* has become a major hospital-acquired strain in many hospitals around the world. *A. baumannii* associated infections are characterized considerable mortality, and using empirical therapy will not satisfactory results due to rapidly increasing resistance to antibiotics.

In this study, *A. baumannii* was isolated in 20% of all bacteriological specimens; this corresponds to similar study carried out by Pathwardhan et al [12]. *A. baumannii* strains were isolated in 23% cases and by Brkic et al [13] in 17.2% of the total isolates. However, in our study the prevalence *A. baumannii* was isolated in 303 samples forming 34.8% of the total gram-negatives. In similar studies same authors reported figures much less 10% [14-16]. Moreover, the prevalence of *A. baumannii*

strains in our ICU was significantly increased from 6.9% in 2011 to 34.1% to 2015 (p=0.002).

The respiratory system is the most common site for *Acinetobacter* infection because of its transient pharyngeal colonization of healthy persons and a high rate of tracheostomy colonization. Among the source of the isolates, most of *A. baumannii* was isolated from tracheostomy tube – 22.1%, followed by 19.1% in tracheal aspirate, 12.5% from bronchealveolar lavage and 11.9% from sputum. Other studies similar to this, were carried out by Villers et al. [17] where prevalence in tracheal aspirate were 24.8% and Jaggi et al [15] as 18% in their studies. *Acinetobacter* associated infections often develop into bacteremia and septicemia, and lower respiratory tract involvement with these strains progresses to bacteremia and septicemia. In our study, the maximum isolates of *Acinetobacter baumannii* were obtained from the respiratory tract, and this finding is consistent with the findings of other similar studies [18-19].

In the period our study the prevalence of *A. baumannii* in the causation of surgical site

infection was caused about 14.5%, moreover, during the study period this was increased from 11.4% to 31.8% ($p=0.049$). Other studies, similar to this, were carried by Jaggi et al [15] reported about 12.5% and Jones et al [20] have shown similar results (11.7%). The risk of urinary tract infections in ICU is connected with the duration of catheterization and increases by 5% each day. In our hospital prevalence of *A. baumannii* associated urinary tract infections were 15.5% (increased from 10.6% to 27.7% $p=0.031$). Other studies by Duszyńska et al have shown similar results (20%) [21].

Bloodstream infections - the leading infectious complications in patients in intensive care unit (ICU), found in 15% of patients with nosocomial infections and in 1% of all hospitalized patients. In our study the prevalence of *A. baumannii* from bloodstream infection were increased from 13.6% in 2011 to 27.2% in 2015 ($p=0.006$).

Antibiotic resistance of *A. baumannii* is a major and leading problem in the ICU. Microbiological clinical studies around the world report high level and increasing resistance rates to antibiotics of *A. baumannii* isolates – are a factor in nosocomial infections [22-24]. Many studies were shown highly resistant rates to all classes of antibiotics. In a study conducted by Yuce et al. [25] reported resistance rates of 98% to ceftazidime, 95% to cefepime, 84% to meropenem, 90% to ciprofloxacin, and 100% to piperacillin-tazobactam. Eser et al. reported same level of resistance rates of 65%, 80%, 98%, 92%, 100%, and 86% for imipenem, amikacin, piperacillin-tazobactam, cefepime, ceftriaxone, tetracycline and trimetoprim-sulfametoxazole, respectively [26].

Resistance rates obtained in our study are also high and gradually increasing to 100% (to quinolones $p=0.003$). The high resistance rates reported in study may be associated with antimicrobial agent usage policies and consumption as well as specific infection programs.

As is known, carbapenems have been the first line treatment for gram-negative infection in ICU patients. In our study, a review of the distributions by year revealed developed that carbapenem resistance rates alarming increased. In 2011 the *A. baumannii* resistant to meropenem and imipenem was found to 76.1%

and 50% respectively, while these resistance rates had increased to 100% both of carbapenems ($p=0.021$ and $p=0.029$, respectively) in 2015.

Actually, Acinetobacter strains are resistant to major classes of antibiotics and retain activity just to colistin and some old toxic antibiotics. In our study all isolates of *A. baumannii* were susceptible to colistin. In this study, examining the five-year average antimicrobial resistance of *A. baumannii* strains, the lowest resistance was found to aminoglycosids. No significant resistance increased in netilmicin (from 0 to 50% $p=0.222$), but this encourages further monitoring of the development of resistance.

Currently, aminoglycoside agents, such as tobramycin and amikacin, are therapeutic options for infection with multidrug-resistant Acinetobacter isolates that retain susceptibility. In our study lower increasing resistant rates were found to gentamicin and tobramycin from 27.3% to 83.3% ($p=0.026$) and from 14.3% to 73.7% ($p=0.016$) respectively. Other studies reported the similar results [27-28].

However, as the resistance against to netilmicin and tobramycin is not very high in our hospital, it can still be used as the drug of choice against multidrug resistant strains of *A. baumannii* but preparations mentioned above are not registered in Kazakhstan.

In conclusion, we report for the first time in Central Kazakhstan the prevalence and resistance rates of *A. baumannii* in ICU in a single tertiary hospital. The present report is alarming because the increasing resistance can lead to no alternative situation on the choice of drugs for the casual treatment of infections caused by extremely resistant *A. baumannii* strains.

In order to reduce the emergence and spread of extremely drug resistant *A. baumannii* strains in the ICU, it is strongly recommended to carry out monitoring (including rapid microbiological diagnostics with the results of antibiotic resistance), comprehensive infection control measures, and optimization of the use of antibiotics in each hospital. Therefore local resistance surveillance programs have the greatest value in the development of appropriate

therapeutic recommendations for specific types of patients and infections.

ACKNOWLEDGMENTS

Acknowledgements: We would like to thank all data collectors and participants whose efforts made this study possible.

Declaration of Conflicting Interests: The authors declare that they have no conflict of interest.

Financial Disclosure: No financial support was received.

REFERENCES

- Paul M, Weinberger M, Siegman-Igra Y, et al. *Acinetobacter baumannii*: emergence and spread in Israeli hospitals 1997-2002. *J Hosp Infect* 2005; 60:256-260.
- Gaynes R, Edwards JR. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. *Clin Infect Dis* 2005; 41:848-854.
- Cheon S, Kim M.J, Yun SJ, Moon J.Y, Kim Y.S. Controlling endemic multidrug-resistant *Acinetobacter baumannii* in intensive care units using antimicrobial stewardship and infection control. *Korean J Intern Med* 2016; 31(2): 367-374.
- Manchanda V, Sanchaita S, Singh NP. Multidrug Resistant *Acinetobacter*. *J Glob Infect Dis* 2010; 2(3): 291-304.
- Eliopoulos G.M, Maragakis L.L, Perl T.M. *Acinetobacter baumannii*: Epidemiology, antimicrobial resistant and treatment options. *Clin Infect Dis* 2008; 46 (8): 1254-1263.
- Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F, et al. Risk-factors for the acquisition of imipenem-resistant *Acinetobacter baumannii* in Spain: a nationwide study. *Clin Microbiol Infect* 2005; 11:874-879.
- Baran G, Erbay A, Bodur H, et al. Risk factors for nosocomial imipenem-resistant *Acinetobacter baumannii* infections. *Intern J Infect Dis* 2008; 12:16-21.
- Kollef MH, Niederman MS. Why *Acinetobacter baumannii* a problem for critically ill patients? *Intensive Care Med* 2015, 41:2170-2172.
- Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Predictors of hospital mortality among septic ICU patients with *Acinetobacter* spp. bacteremia: a cohort study. *BMC Infect Dis* 2014; 14:572.
- Shakibaie MR, Adeli S, Salehi MH. Antibiotic resistance patterns and extended-spectrum β -lactamase production among *Acinetobacter* spp. isolated from an ICU of a hospital in Kerman, Iran. *Antimicrob Resist Infect Control* 2012; 1:1-8.
- Guidelines of standards for microbiologic tests in the laboratory of clinical microbiology. Astana.2008:11-12
- Patwardhan RB, Dhakephalkar PK, Niphadkar KB, Chopade BA. A study on nosocomial pathogens in ICU with special reference to multiresistant *Acinetobacter baumannii* harbouring multiple plasmids. *Indian J Med Res* 2008; 178-187.
- Brkic DV, Stanko A.P, Plesko S, Tripkovic V, Bedenic B. *Acinetobacter baumannii* microbiological and phenotypic characteristics of isolates from Intensive Care Unit of the Department of Internal Medicine at the University Hospital Centre in Zagreb over a four-year period. *Signa Vitae* 2015; 10(1):13-15.
- Omer MI, Gumaa SA, Hassan AA, et al. Prevalence and resistance profile of *Acinetobacter baumannii* clinical isolates from a Private Hospital in Khartoum, Sudan. *American J Microb Research* 2015; 3(2): 76-79.
- Jaggi N, Sissodia P, Sharma L. *Acinetobacter baumannii* isolates in a tertiary care hospital: antimicrobial resistance and clinical significance. *J Microbiol Infect Dis* 2012; 2(2): 57-63.
- Uwingabiye J, Frikh M, Lemnouer A. et al. *Acinetobacter* infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. *Pan Afr Med J* 2016; 23: 191.
- Villers D, Espase E, Coste-Burel M, et al. Nosocomial *Acinetobacter baumannii* infections: Microbiological and clinical epidemiology. *Ann Intern Med* 1998; 129:182-189.
- Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007; 12:939-951.
- Begum S, Hasan F, Hussain S, Shah A. A. Prevalence of multi drug resistant *Acinetobacter baumannii* in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. *Pak J Med Sci* 2013; 29(5): 1253-1258.
- Jones M, Donegan N, Saiines S, et al. *Acinetobacter* in sternal surgical site infections after cardiac surgery: Case control to determine significance and outcome. *Am J Infect Control* 2005; 33:169-170.
- Duszyńska W, Rosenthal V.D, Szczyński A. et al. Urinary tract infections in intensive care unit patients - a single-centre, 3-year observational study according to the INICC project. *Anaesthesiology Intensive Therapy* 2016; 48(1):1.

Kommentar [WU1]: This reference is not acceptable. Should be completed or shown in the text in a parenthesis

22. Izadpour F, Ranjbari N, Aramesh M. et al. An investigation of antibacterial resistance patterns among *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates collected from ICU of a University-affiliated hospital in Ahvaz, Iran. *Jundishapur J Microbiol* 2016; 9(8):e35624.
23. Celik C, Gozel M, Dayi F. Increasing antimicrobial resistance in nosocomial pathogens; multidrug-resistant, extensively drug-resistant and pandrug-resistant *Acinetobacter baumannii*. *J Microbiol Infect Dis* 2014; 4 (1):7-12.
24. Yadegarinia D, Abedy S, Gachkar L, Roodsari S. Prevalence and drug resistance of *Acinetobacter baumannii* in ICU of a teaching hospital. *J Appl Environ Biol Sci* 2013; 3(9):22-27.
25. Yüce A, Yapar N, Kutsoylu OE. Evaluation of antibiotic resistance patterns of *Pseudomonas aeruginosa* and *Acinetobacter* spp. strains isolated from intensive care patients between 2000-2002 and 2003-2006 periods in Dokuz Eylül University Hospital, Izmir. *Mikrobiyol Bul* 2009; 43:195-202.
26. Eser ÖK, Ergin A, Hasçelik G. Antimicrobial resistance and existence of metallo-beta-lactamase in *Acinetobacter* species isolated from adult patients. *Mikrobiyol Bul* 2009; 43:383-390.
27. Aliakbarzade K, Farajnia S, Karimi Nik A, Zarei F, Tanomand A. Prevalence of Aminoglycoside Resistance Genes in *Acinetobacter baumannii* Isolates. *Jundishapur J Microbiol* 2014; 7(10):e11924.
28. Akers KS., Chaney C, Barsoumian A. Aminoglycoside resistance and susceptibility testing errors in *Acinetobacter baumannii*-calcoaceticus complex. *J Clin Microb* 2010; 48:1132-1138.